Skip to main content
Evidence Snapshot

Alpha-2A adrenergic receptor

CHEMBL327 SINGLE PROTEIN Rattus norvegicus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:40Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL327
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Alpha-2A adrenergic receptor as ChEMBL target CHEMBL327, mapped to UniProt P22909. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Alpha-2A adrenergic receptor
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL327
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P22909
Alpha-2A adrenergic receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Alpha-2A adrenergic receptor matters

As of 2026-09-13

Alpha-2A adrenergic receptor is reviewed as Alpha-2A adrenergic receptor (UniProt P22909); the current evidence base includes 8 approved drugs, 171 compounds, and 51 assays, with lead potency reaching pChEMBL 10.8.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 171 compounds, and 51 assays for this target. The dominant activity type is KI. CHEMBL778 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL778 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
8 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Alpha-2A adrenergic receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P22909, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

171
Total Compounds
51
Total Assays
8
Approved Drugs
IC50: 3.0, KI: 109.0, KD: 7.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL778
 10.8 Ki Approved
No preferred name
CHEMBL286269
 9.5 Ki —
No preferred name
CHEMBL134
 9.4 Ki Approved
No preferred name
CHEMBL14376
 9.4 IC50 Approved
No preferred name
CHEMBL284213
 9.2 Ki —

Approved Drugs

Structure Compound First Approval
ILOPERIDONE
CHEMBL14376
 2009
DEXMEDETOMIDINE
CHEMBL778
 1999
RISPERIDONE
CHEMBL85
 1993
CISAPRIDE
CHEMBL1729
 1993
CLOZAPINE
CHEMBL42
 1989
CLONIDINE
CHEMBL134
 1974
PHENTOLAMINE
CHEMBL597
 1952
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:40Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL327